Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-9378
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin ; volume:16 ; number:1 ; day:7 ; month:1 ; year:2021 ; pages:1-11 ; date:12.2021
Infectious agents and cancer ; 16, Heft 1 (7.1.2021), 1-11, 12.2021
- Urheber
-
Coldiron, Matthew E.
Gutierrez Zamudio, Ana Gabriela
Manuel, Rolanda
Luciano, Gilda
Rusch, Barbara
Ciglenecki, Iza
Telnov, Alex
Grais, Rebecca F.
Trellu, Laurence Toutous
Molfino, Lucas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13027-020-00341-4
- URN
-
urn:nbn:de:101:1-2021020805293120885589
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Coldiron, Matthew E.
- Gutierrez Zamudio, Ana Gabriela
- Manuel, Rolanda
- Luciano, Gilda
- Rusch, Barbara
- Ciglenecki, Iza
- Telnov, Alex
- Grais, Rebecca F.
- Trellu, Laurence Toutous
- Molfino, Lucas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
Behandlung des Kaposi Sarkoms bei AIDS mit liposomal verkapseltem Doxorubicin : Ergebnisse einer Phase I-II Studie
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
Behandlung des Kaposi Sarkoms bei AIDS mit liposomal verkapseltem Doxorubicin : Ergebnisse einer Phase I-II Studie
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)